NYKODE THERAPEUTICS ASA: årsregnskap 2012 vs 2011
Shrank 13% on revenue, fresh owner capital
approved 2013-04-17; registry 2013-06-05; journal 2013 432803
Summary
What changed
Comparing Årsregnskap 2012 with 2011 for NYKODE THERAPEUTICS ASA. Revenue 1.32m NOK → 1.15m NOK (-13.2%). Equity 340.8k NOK → 108.6k NOK.
On the constructive side: cash rose; owners injected capital. Pressures included: revenue fell; operating result weakened; equity eroded.
Also worth watching: thin equity buffer. All figures are taken from the published annual accounts for NYKODE THERAPEUTICS ASA.
At a glance
Scorecard
What improved
-
↑
Cash rose
Bank deposits 2.61m NOK → 6.38m NOK (+144.8% YoY). Calculated
-
↑
Owners injected capital
Paid-in equity rose 8.28m NOK → 17.73m NOK (+9.45m NOK). Reported fact
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 1.32m NOK to 1.15m NOK (-13.2% YoY). Calculated
-
↓
Operating result weakened
Operating result -2.51m NOK → -2.68m NOK (op. margin -190.0% → -233.6%). Calculated
-
↓
Equity eroded
Book equity 340.8k NOK → 108.6k NOK (equity ratio 7.2% → 1.4%). Calculated
-
↓
Payroll up without matching revenue
Salary cost 600.5k NOK → 2.07m NOK (45% → 181% of revenue). Calculated
Things to notice
-
·
Thin equity buffer
Equity ratio is 1.4% of assets — limited loss-absorbing capacity on a stand-alone basis. Interpretation